WuXi, Lilly partner on dyslipidemia candidate

WuXi PharmaTech Inc. (NYSE:WX) and Eli Lilly and Co. (NYSE:LLY) partnered to develop and commercialize an undisclosed small molecule in China to reduce cardiovascular events in patients with dyslipidemia.

WuXi plans to lead regulatory, development and manufacturing activities in China, which would allow the candidate to benefit from China FDA's accelerated regulatory pathway for domestic drugs. Lilly, which discovered the candidate, will be responsible for commercialization. ...